{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T18:28:39Z","timestamp":1793989719396,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018731","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018731","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-73018-y","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:34:40Z","timestamp":1782160480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["HRS-7535, an oral small-molecule GLP-1 receptor agonist, in Chinese adults with obesity without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Weijun","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7249-6445","authenticated-orcid":false,"given":"Qifu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicen","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3344-3540","authenticated-orcid":false,"given":"Yiming","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"73018_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"A Afshin","year":"2017","unstructured":"Afshin, A. et al. Health effects of overweight and obesity in 195 Countries over 25 Years. N. Engl. J. Med. 377, 13\u201327 (2017).","journal-title":"N. Engl. J. Med."},{"key":"73018_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","volume":"388","author":"E Di Angelantonio","year":"2016","unstructured":"Di Angelantonio, E. et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 388, 776\u2013786 (2016).","journal-title":"Lancet"},{"key":"73018_CR3","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley, T. M. et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143, e984\u2013e1010 (2021).","journal-title":"Circulation"},{"key":"73018_CR4","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/S0140-6736(16)00271-3","volume":"387","author":"GA Bray","year":"2016","unstructured":"Bray, G. A., Fr\u00fchbeck, G., Ryan, D. H. & Wilding, J. P. Management of obesity. Lancet 387, 1947\u20131956 (2016).","journal-title":"Lancet"},{"key":"73018_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","volume":"22","author":"WT Garvey","year":"2016","unstructured":"Garvey, W. T. et al. American Association of clinical endocrinologists and American College Of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr. Pract. 22, 1\u2013203 (2016).","journal-title":"Endocr. Pract."},{"key":"73018_CR6","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1503\/cmaj.191707","volume":"192","author":"S Wharton","year":"2020","unstructured":"Wharton, S. et al. Obesity in adults: a clinical practice guideline. Cmaj 192, E875\u2013e891 (2020).","journal-title":"Cmaj"},{"key":"73018_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1089\/dia.2019.0185","volume":"22","author":"JD Bucheit","year":"2020","unstructured":"Bucheit, J. D. et al. Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist. Diab. Technol. Ther. 22, 10\u201318 (2020).","journal-title":"Diab. Technol. Ther."},{"key":"73018_CR8","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","volume":"344","author":"T Vilsb\u00f8ll","year":"2012","unstructured":"Vilsb\u00f8ll, T., Christensen, M., Junker, A. E., Knop, F. K. & Gluud, L. L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. Bmj 344, d7771 (2012).","journal-title":"Bmj"},{"key":"73018_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"73018_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop, F. K. et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 402, 705\u2013719 (2023).","journal-title":"Lancet"},{"key":"73018_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton, S. et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N. Engl. J. Med. 389, 877\u2013888 (2023).","journal-title":"N. Engl. J. Med."},{"key":"73018_CR12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/dom.15383","volume":"26","author":"J Wu","year":"2024","unstructured":"Wu, J. et al. Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: a phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial. Diab. Obes. Metab. 26, 901\u2013910 (2024).","journal-title":"Diab. Obes. Metab."},{"key":"73018_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"O\u2019Neil, P. M. et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 392, 637\u2013649 (2018).","journal-title":"Lancet"},{"key":"73018_CR14","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","volume":"393","author":"S Wharton","year":"2025","unstructured":"Wharton, S. et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N. Engl. J. Med. 393, 1796\u20131806 (2025).","journal-title":"N. Engl. J. Med."},{"key":"73018_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne, L. J. et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. 393, 26\u201336 (2025).","journal-title":"N. Engl. J. Med."},{"key":"73018_CR16","doi-asserted-by":"publisher","first-page":"107866","DOI":"10.1016\/j.phrs.2025.107866","volume":"219","author":"M Marassi","year":"2025","unstructured":"Marassi, M. et al. Sex differences in the weight response to GLP-1RA in people with type 2 diabetes. A long-term longitudinal real-world study. Pharmacol. Res. 219, 107866 (2025).","journal-title":"Pharmacol. Res."},{"key":"73018_CR17","doi-asserted-by":"publisher","first-page":"116623","DOI":"10.1016\/j.bcp.2024.116623","volume":"230","author":"JFA Model","year":"2024","unstructured":"Model, J. F. A. et al. Interactions between glucagon like peptide 1 (GLP-1) and estrogens regulates lipid metabolism. Biochem. Pharmacol. 230, 116623 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"73018_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","volume":"12","author":"Y Mu","year":"2024","unstructured":"Mu, Y. et al. Efficacy and safety of once weekly semaglutide 2\u00b74 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.  Lancet Diab. Endocrinol. 12, 184\u2013195 (2024).","journal-title":"Lancet Diab. Endocrinol."},{"key":"73018_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer, X. et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N. Engl. J. Med. 373, 11\u201322 (2015).","journal-title":"N. Engl. J. Med."},{"key":"73018_CR20","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S2468-1253(17)30285-6","volume":"2","author":"H Halawi","year":"2017","unstructured":"Halawi, H. et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol. Hepatol. 2, 890\u2013899 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"73018_CR21","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden, T. A. et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int. J. Obes. 37, 1443\u20131451 (2013).","journal-title":"Int. J. Obes."},{"key":"73018_CR22","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman, A. et al. Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int. J. Obes. 40, 1310\u20131319 (2016).","journal-title":"Int. J. Obes."},{"key":"73018_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/oby.22726","volume":"28","author":"TA Wadden","year":"2020","unstructured":"Wadden, T. A. et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity 28, 529\u2013536 (2020).","journal-title":"Obesity"},{"key":"73018_CR24","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup, A. et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606\u20131616 (2009).","journal-title":"Lancet"},{"key":"73018_CR25","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden, T. A. et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. Jama 325, 1403\u20131413 (2021).","journal-title":"Jama"},{"key":"73018_CR26","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino, D. et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. Jama 325, 1414\u20131425 (2021).","journal-title":"Jama"},{"key":"73018_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/dom.14280","volume":"23","author":"M Friedrichsen","year":"2021","unstructured":"Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A. & Skovgaard, D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diab. Obes. Metab. 23, 754\u2013762 (2021).","journal-title":"Diab. Obes. Metab."},{"key":"73018_CR28","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","volume":"49","author":"A Ismaiel","year":"2025","unstructured":"Ismaiel, A. et al. Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis. Int. J. Obes.49, 1946\u20131957 (2025).","journal-title":"Int. J. Obes."},{"key":"73018_CR29","doi-asserted-by":"crossref","unstructured":"Gorgojo-Mart\u00ednez, J. J. et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. J. Clin. Med. 12, 145 (2022).","DOI":"10.3390\/jcm12010145"},{"key":"73018_CR30","doi-asserted-by":"publisher","first-page":"e2314493","DOI":"10.1001\/jamanetworkopen.2023.14493","volume":"6","author":"AR Saxena","year":"2023","unstructured":"Saxena, A. R. et al. Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial. JAMA Netw. Open 6, e2314493 (2023).","journal-title":"JAMA Netw. Open"},{"key":"73018_CR31","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1111\/dom.15150","volume":"25","author":"E Pratt","year":"2023","unstructured":"Pratt, E. et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diab. Obes. Metab. 25, 2642\u20132649 (2023).","journal-title":"Diab. Obes. Metab."},{"key":"73018_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jcpt.13225","volume":"45","author":"J Trujillo","year":"2020","unstructured":"Trujillo, J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J. Clin. Pharm. Ther. 45, 43\u201360 (2020).","journal-title":"J. Clin. Pharm. Ther."},{"key":"73018_CR33","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino, D. M. et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. Jama 327, 138\u2013150 (2022).","journal-title":"Jama"},{"key":"73018_CR34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos, T. D., Panagiotopoulou, T. V. & Elisaf, M. S. Adverse Effects of GLP-1 receptor agonists.  Rev. Diabet. Stud. Rds. 11, 202\u2013230 (2014).","journal-title":"Rev. Diabet. Stud. Rds."},{"key":"73018_CR35","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies, M. et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. Jama 318, 1460\u20131470 (2017).","journal-title":"Jama"},{"key":"73018_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dom.16005","volume":"27","author":"NB Amin","year":"2025","unstructured":"Amin, N. B. et al. Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study. Diab. Obes. Metab. 27, 215\u2013227 (2025).","journal-title":"Diab. Obes. Metab."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73018-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:02:25Z","timestamp":1786014145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73018-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73018"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73018-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.Z., Z.Y., C.S., and T.Z. are employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7867"}}